International Journal of Clinical Research

Objective: To evaluate the efficacy and safety of azitromycin combined with Purdue blue in the treatment of pediatric mycoplasma pneumonia. Methods The Cochrane Central Register of Controlled Trials, Joanna Briggs Institute Library, Web of Science, Science, MEDLINE, PubMed, Web of Knowledge CNKI, Wanfang Data and CBM were searched to collect randomized controlled trials (RCTs) on using azitromycin combined with Purdue blue in the treatment of pediatric mycoplasma pneumonia. The quality of the studies was critically appraised and data were extracted by 2 reviewers independently, and meta-analysis was conducted. Results A total of 8 RCTs were chosen, involving 883 patients. The results of meta-analysis demonstrated that when used for children with mycoplasma pneumonia, azitromycin combined with Purdue blue could increase efficacy,CD4+ T cell/CD8+ T cell.Antipyretic time, C-reactive protein, Interleukin-6, Interleukin-8 and interferon-γ in azitromycin combined with Purdue blue group were significantly lower than those in azitromycin group. There was no significant difference between the two groups in the aspects of procalcitonin, CD3+ T cell, CD4+ T cell, CD8+ T cell, CD4+ T cell/CD8+ T cell and adverse effects. Conclusion Azitromycin combined with Purdue blue can effectively increase efficacy, shorten the time of Antipyretic, improve the T lymphocyte subsets, reduce the concentration of serum inflammatory factors, improve the immune level of the body, and promote the rapid absorption of inflammation in children with mycoplasma pneumonia.

Pediatric Mycoplasma Pneumonia; Azitromycin; Purdue Blue; Meta-Analysis